Question explored with the scientific record
Conversation so far
- 1 Is an immunosuppressant shot worth it for a AS?
- 2 Which AS symptoms did trials improve most, pain or stiffness or function?
- 3 What are the most common serious risks of TNF blockers vs NSAIDs?
- 4 Tell me all the pros and cons about adalimumab
Answered on this page ↓
Tell me all the pros and cons about adalimumab
The short version: adalimumab clearly reduces AS symptoms and inflammation in the short term, but the trials are small, short, and mostly industry-run, and the long-term safety picture is thin.
For AS, the benefit is real. In a pooled analysis of randomized trials, adalimumab roughly doubled the chance of an ASAS20 response versus placebo (RR 2.26) and more than doubled a 50% BASDAI improvement (RR 2.82) [1]. One placebo-controlled trial put ASAS20 at 58.2% versus 20.6% at week 12 [5]. It also eased enthesitis and peripheral arthritis [3], and in children cut spinal inflammation scores by 66% [4].
The harms are real too. Any adverse event rose 23% versus placebo, and injection-site reactions nearly fivefold [1]. Serious infections, TB reactivation, and opportunistic fungal infections are the documented class risks [8][10][11]. TB incidence on adalimumab ran 91 to 308 per 100,000 per year in one review [13], and 4 of 7 active TB cases in a Turkish cohort were on adalimumab [12]. Rare but severe events include granulomatous interstitial nephritis [6], fatal VZV vasculopathy [9], and erythema multiforme [7].
| Outcome | Adalimumab | Placebo |
|---|---|---|
| ASAS20, week 12 | 58.2% | 20.6% [5] |
| BASDAI 50%, week 12 | 45.2% | 15.9% [5] |
| Any adverse event (RR) | 1.23 | reference [1] |
| Injection-site reaction (RR) | 4.88 | reference [1] |
What the trials do not show: whether adalimumab changes long-term structural damage. One two-year study found spinal progression of 0.8 versus 0.9 in an untreated historical cohort, no meaningful difference [2]. That is a surrogate, not a hard outcome. No retrieved trial compared adalimumab to a true untreated group over years for serious infection or death. Most trials are short and industry-sponsored.
My call: for active AS with inadequate NSAID response, adalimumab is worth trying, with TB screening first and awareness of infection risk. Confidence: moderate on short-term benefit, low on long-term safety.
Sources used 13
-
Randomized, placebo controlled and double‐blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta‐analysis
This meta-analysis evaluates the efficacy and safety of adalimumab in treating ankylosing spondylitis, demonstrating significant improvements in clinical outcomes compared to placebo, while highlighting the need for caution regarding adverse events.
DOI: 10.1111/1756-185X.12245 -
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
This study evaluates the radiographic progression of ankylosing spondylitis in patients treated with adalimumab over two years, finding no significant difference in progression compared to a historical cohort of anti-TNF-naïve patients.
DOI: 10.1186/ar2794 -
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
This study investigates the effectiveness of adalimumab in treating enthesitis and peripheral arthritis in patients with ankylosing spondylitis, demonstrating significant improvements in both conditions over a 12-week period.
DOI: 10.1186/ar2953 -
Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
This Phase III clinical trial demonstrates the efficacy of adalimumab in reducing disease activity in juvenile ankylosing spondylitis over a 12-week period compared to placebo.
DOI: 10.1186/1546-0096-9-s1-p201 -
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of adalimumab, a fully human monoclonal antibody targeting TNF-α, in patients with active ankylosing spondylitis, demonstrating significant improvements in disease activity and…
DOI: 10.1002/art.21913 -
Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab
This case report describes a patient with ankylosing spondylitis who developed drug-induced granulomatous interstitial nephritis after 18 months of treatment with adalimumab, highlighting the need for careful monitoring of autoimmune reactions in patients receiving TNF-α inhibit…
DOI: 10.1053/j.ajkd.2010.08.019 -
Erythema multiforme during anti–tumor necrosis factor treatment for plaque psoriasis
This case report describes a 67-year-old man who developed erythema multiforme after treatment with the TNF-alpha inhibitor adalimumab for plaque psoriasis, suggesting a potential class effect of TNF-alpha inhibitors in causing this condition.
DOI: 10.1016/j.jaad.2009.04.048 -
Adalimumab: a review of side effects
This review discusses the side effects of adalimumab, a human monoclonal TNF-α antibody used for treating rheumatoid arthritis and other autoimmune diseases, highlighting its favorable side effect profile compared to traditional treatments but noting significant risks such as se…
DOI: 10.1517/14740338.4.4.637 -
Fatal Varicella-Zoster Virus Vasculopathy Associated With Adalimumab Therapy
This study presents a case of a 66-year-old woman who developed fatal varicella-zoster virus vasculopathy with multifocal cerebral hemorrhage after receiving adalimumab therapy for rheumatoid arthritis, highlighting the potential severe neurological complications associated with…
DOI: 10.1001/archneurol.2011.3741 -
Long-term risks associated with biologic response modifiers used in rheumatic diseases
A comprehensive review of long-term safety risks associated with tumor necrosis factor-alpha (TNF-α) antagonists used in rheumatic diseases, focusing on postmarketing adverse events such as infections (notably tuberculosis and opportunistic infections), lymphoma, drug-induced lu…
DOI: 10.1097/00002281-200405000-00006 -
Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases
This is a comprehensive review of the spectrum and mechanisms of serious infections associated with tumor necrosis factor (TNF) inhibitors and other anticytokine therapies in inflammatory diseases, summarizing clinical trial and postmarketing data (notably TB, histoplasmosis, li…
DOI: 10.1177/0885066604267854 -
Risk of Latent Tuberculosis Infection Reactivation in Patients Treated with Tumor Necrosis Factor Antagonists: A Five-Year Retrospective Study
A five-year retrospective cross-sectional study at Çanakkale Onsekiz Mart University Hospital in Türkiye assessed TB reactivation risk among 519 patients treated with TNF-α antagonists, comparing those who did and did not receive LTBI treatment, and found 7 active TB cases (1.34…
DOI: 10.3390/tropicalmed10070190 -
Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
This review evaluates the risk of tuberculosis (TB) in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving infliximab, adalimumab, and etanercept, revealing a higher incidence of TB with monoclonal antibodies compared to etanercept and h…
DOI: 10.3899/jrheum.140102